In a COPD patient with ≥2 moderate or severe exacerbations per year despite optimized inhaled triple therapy (inhaled corticosteroid + long‑acting β2‑agonist + long‑acting muscarinic antagonist) and a peripheral blood eosinophil count ≥300 cells/µL, which biologic agents are recommended?

Biologic Agents in COPD with Persistent Exacerbations Despite Triple Therapy

For COPD patients with ≥2 moderate or ≥1 severe exacerbations per year despite optimized triple therapy and blood eosinophils ≥300 cells/µL, biologic agents (dupilumab or mepolizumab) are now recommended as add-on therapy, though the 2023 Canadian Thoracic Society guidelines do not yet include biologics in their recommendations—instead prioritizing macrolide antibiotics, roflumilast, or N-acetylcysteine for this population.

Current Guideline-Based Approach (Pre-Biologic Era)

The 2023 Canadian Thoracic Society guidelines provide a clear escalation pathway for patients who continue to exacerbate despite triple therapy 1:

First-Line Add-On: Macrolide Maintenance Therapy

• Strong recommendation for adding macrolide antibiotics (e.g., azithromycin) to triple therapy in patients with persistent exacerbations 1
• Critical safety requirements before initiating:
  • Normal QT interval on ECG (to prevent cardiac arrhythmias)
  • No significant drug interactions with concurrent medications
  • No evidence of indolent or active atypical mycobacterial infection
• Important caveat: Benefits studied over 1 year must be weighed against risks of microbial resistance, hearing impairment, and QT prolongation 1

Alternative Add-On Therapies

For patients with chronic bronchitic phenotype who continue to exacerbate on triple therapy 1:

• Roflumilast (PDE4 inhibitor) - particularly for severe to very severe airflow obstruction
• N-acetylcysteine (antioxidant mucolytic)
• These carry a weak recommendation with lower certainty of evidence compared to macrolides 1

Critical Point About ICS Withdrawal

Do NOT step down from triple therapy in this population 1:

• Withdrawing ICS increases risk of moderate-severe exacerbations
• This risk is especially pronounced in patients with eosinophils ≥300 cells/µL
• May also lower health status and lung function

Emerging Biologic Therapy (GOLD 2026)

The 2026 GOLD report introduces a paradigm shift by formally recommending biologic agents 2:

Approved Biologics for COPD

• Dupilumab (anti-IL-4/IL-13)
• Mepolizumab (anti-IL-5)

Patient Selection Criteria

Biologics are indicated as add-on therapy for patients with:

• Exacerbation-prone disease (≥2 moderate or ≥1 severe exacerbations/year)
• Elevated blood eosinophils (≥300 cells/µL threshold emphasized)
• Persistent exacerbations despite optimized dual bronchodilation or triple therapy
• Type 2 inflammatory phenotype 2

Evidence Supporting Biologics

Real-world data demonstrates the substantial burden in this population 3:

• Patients with ≥2 moderate or ≥1 severe exacerbations on triple therapy with eosinophils ≥300 cells/µL have mean exacerbation rates of 1.56 per year
• These patients have significantly higher healthcare resource utilization and medical costs
• Approximately 17-40% of COPD patients have type 2 inflammation characterized by elevated eosinophils 4, 3

Clinical Algorithm for Your Patient

For a patient with ≥2 exacerbations/year on triple therapy with eosinophils ≥300 cells/µL:

1. Verify triple therapy optimization:

   • Confirm adherence to single-inhaler triple therapy (ICS/LABA/LAMA)
   • Ensure proper inhaler technique
   • Confirm adequate ICS dose (moderate dose preferred for mortality benefit)

2. First escalation option (based on 2023 CTS guidelines):

   • Add macrolide maintenance therapy (azithromycin) IF:
     • Normal baseline ECG (QTc)
     • No drug interactions
     • Negative atypical mycobacterial screening
   • OR consider roflumilast/N-acetylcysteine if chronic bronchitic phenotype

3. Emerging option (based on GOLD 2026):

   • Consider biologic therapy (dupilumab or mepolizumab) for patients with:
     • Confirmed eosinophilic phenotype (≥300 cells/µL)
     • Persistent exacerbations despite triple therapy ± macrolides
     • Type 2 inflammatory features

Important Caveats and Limitations

Regarding Biologics

• Cost-effectiveness remains uncertain 2
• Limited real-world evidence for long-term outcomes
• Generalizability concerns—most trials excluded patients with significant comorbidities
• Access barriers in many healthcare systems
• Not yet incorporated into major North American guidelines (CTS 2023)

Regarding Eosinophil Thresholds

• Blood eosinophil counts show biological variability
• The ≥300 cells/µL threshold is well-established for ICS benefit and now biologic consideration
• Measurements should be obtained when patient is stable (≥14 days after systemic corticosteroids) 3
• Higher eosinophil counts (≥300 cells/µL) correlate with worse outcomes: 55.9% of patients with eosinophils ≥300 cells/µL experienced ≥2 moderate or ≥1 severe exacerbations versus 47.1% with <150 cells/µL 5

Disease Burden Context

Real-world data shows that 53.7% of patients on triple therapy continue to have at least one moderate or severe exacerbation, with mean exacerbation rates of 1.37 per year 4. This substantial residual risk, particularly in the eosinophilic subgroup, underscores the need for additional therapeutic options beyond traditional triple therapy.